Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin

Abstract

Inhibition of dipeptidyl peptidase-4 (DPP-4) as a novel therapy for type 2 diabetes is based on prevention of the inactivation process of bioactive peptides, the most important in the context of treatment of diabetes of which is glucagon-like peptide-1(GLP-1). Most clinical experience with DPP-4 inhibition is based on vildagliptin (Galvus^R, Novartis) and sitagliptin (Januvia^R, Merck). These compounds improve glycemic control both in monotherapy and in combination with other oral hyperglycemic agents. Both have also been shown to efficiently improve glycemic control when added to ongoing metformin therapy in patients with inadequate glycemic control. Under that condition, they reduce HbA_1c levels by 0.65%–1.1% (baseline HbA_1c 7.2–8.7%) in studies up to 52 weeks of duration in combination versus continuous therapy with metformin alone. Sitagliptin has also been examined in initial combination therapy with metformin have; HbA_1c was reduced by this combination by 2.1% (baseline HbA_1c 8.8%) after 24 weeks of treatment. Both fasting and prandial glucose are reduced by DPP-4 inhibition in combination with metformin in association with improvement of insulin secretion and insulin resistance and increase in concentrations of active GLP-1. The combination of DPP-4 inhibition and metformin has been shown to be highly tolerable with very low risk of hypoglycemia. Hence, DPP-4 inhibition in combination with metformin is an efficient, safland tolerable combination therapy for type 2 diabetes.

Keywords:

• DPP-4 inhibition
• sitagliptin
• vildagliptin
• metformin
• type 2 diabetes